
|Videos|January 8, 2021
C. Difficile Treatment: Bezlotoxumab
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Advertisement
Episodes in this series

Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Prospective Game Changer: Lenacapavir for HIV Preexposure Prophylaxis
2
Unlocking New Defenses: The Changing Landscape of Candida auris Management
3
What's New in 2025: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
4
COVID-19: The Gaps in Science Communication
5











































































































































































































































































































































